REQ-2021-055 Supplementary material

MHDA DISPENSATION CIRCUIT SATISFACTION SURVEY THROUGH COMMUNITY PHARMACY OFFICES-COVID-19 PANDEMIC

1. In general, how would you indicate your degree of satisfaction with the new medication dispensing circuit through the Community Pharmacy?

- Very satisfied

- Satisfied

- Dissatisfied

- Indifferent

2. Taking into account that this dispensing circuit was designed to facilitate the collection of medication, which one do you prefer?

- Hospital Pharmacy Dispensing

- Community Pharmacy Dispensing

- Indifferent

3. How would you rate (from 0 to 10) this new form of dispensing medication, taking

into account its purpose of facilitating ART collection (question 3)

Qualification:

4. When choosing the Community Pharmacy Office, you prioritize:

- Community Pharmacy close to your home (in the same neighborhood) (closer to home)

- Community Pharmacy away from your home (in another neighborhood) // (greater importance to privacy)

- Indifferent

5. What advantages do you consider that the dispensing of the medication at the Community Pharmacy has brought you? (Question that can have more than 1 answer)

- Greater proximity to home

- Reduction of waiting time

- Reduction of the risk of contagion in the context of the COVID-19 pandemic (crowds, contact with other patients, health personnel, means of transport to the Hospital, etc....)

- Resolution of doubts (interactions with food, adverse effects, others)

- Others, specify which ones? :

6. Regarding the potential interactions (PDDIs) between ART and other possible concomitant drugs that you take:

- Concomitant medication and PDDIs were confirmed, advice was given

- Concomitant medication and PDDIs confirmed, no advice given

- Concomitant medication and PDDIs were not confirmed

POTENTIAL DRUG-DRUG INTERACTIONS (PDDIs) BETWEEN ANTIRETROVIRAL TREATMENTE (ART) AND OTHER MEDICINES CONCOMITANTS. PERIOD 2020-2021

PATIENT ID:					DATE:		
AGE:							
SEX:	SEX:			Ethnicity:			
1.	AR • • •	T Actual ART star Date of last vis Date of last and CV HIV last cor CD4T last chec ART Adherence 90%	it (virtual-face- alytical control ntrol: k:		<50% 🗆		
2.	Со	oncomitant medication:					
	•		No D Polypharmacy (>5 drugs) D mber of concomitant drugs you take: mes of concomitant drugs:				
3.	No	on-prescribed drugs:					
	•	"ChemSex" If yes, how free			Frequentl		Which?
		If yes, follow-up by psychiatry: Yes □		N	o 🗆		
	• • • •	Herbalism: Vitamin Compl Other drugs co Smoker: Alcohol consur If yes, how free	nsumption: nption:	Yes Yes Yes Yes Yes times	NG NG NG	o 🗆 o 🗆 o 🗆 o 🗆 y 🗆	Which? Which? Ex-Smoker 🗆
4.	PD	DDIs (Liverpool HIV Interactions)					
	•	Do Not Coadminister HIV Medication: Co-Medication:					
	•	Potential Interaction HIV Medication:					
		Co-Medication:					

- Potential Weak Interaction
 HIV Medication:
 Co-Medication:
- No Interaction Expected
 HIV Medication:
 Co-Medication: